Drugmakers will likely have tens of millions of doses of coronavirus vaccines in the early part of next year, Anthony Fauci, the top U.S. infectious diseases official, said in a Reuters interview.
Russia’s minister of health, Mikhail Murashko, indicated that the country is planning a nationwide program to vaccinate its population against Covid-19 starting in October.
U.S. drugmaker Eli Lilly & Co. is beginning a late-stage trial to study whether one of the company’s experimental Covid-19 antibody treatments can prevent the spread of the virus in residents and staff at U.S. nursing homes.
Moderna Inc. and Pfizer Inc. launched two 30,000-subject trials of Covid-19 vaccines that could clear the way for regulatory approval and widespread use by the end of 2020.
Moderna Inc. received an additional $472 million from the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) to support development of the company’s novel coronavirus vaccine.
The National Institutes of Health (NIH) announced plans to launch a “flurry” of large-scale clinical trials for treating Covid-19.
The United States shattered the country’s daily record for coronavirus infections on Thursday, reporting more than 77,000 new cases as the number of deaths in a 24-hour period rose by nearly 1,000, according to a Reuters tally.
According to data published in The New England Journal of Medicine, a Phase I trial of Moderna’s mRNA vaccine against SARS-CoV-2 demonstrated promising safety and immune response in all patients involved in the study.
Moderna Inc.’s experimental vaccine for Covid-19 showed mRNA-1273 was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study, U.S. researchers reported.
U.S. industrial conglomerate 3M Co. has partnered with the Massachusetts Institute of Technology to develop a rapid antigen test for COVID-19.
